|
Variables
|
All patients n (%)
|
Training set n (%)
|
Validation set n (%)
|
P
|
|---|
|
Total
|
1541 (100.0)
|
1079 (70.0)
|
462 (30.0)
| |
|
Age, years
| | | |
0.984
|
|
< 50
|
413 (26.8)
|
290 (26.9)
|
124 (26.8)
| |
|
50–60
|
609 (39.5)
|
425 (39.4)
|
184 (39.8)
| |
|
> 60
|
518 (33.6)
|
364 (33.7)
|
154 (33.3)
| |
|
Tumor size, cm
| | | |
0.325
|
|
≤ 12
|
810 (52.6)
|
576 (53.4)
|
234 (50.6)
| |
|
> 12
|
731 (47.4)
|
503 (46.6)
|
228 (49.4)
| |
|
Race
| | | |
0.524
|
|
White
|
1154 (74.9)
|
813 (75.3)
|
341 (73.8)
| |
|
Other
|
387 (25.1)
|
266 (24.7)
|
121 (26.2)
| |
|
Laterality
| | | |
0.289
|
|
Unilateral
|
1374 (89.2)
|
968 (89.7)
|
406 (87.9)
| |
|
Bilateral
|
167 (10.8)
|
111 (10.3)
|
56 (12.1)
| |
|
AJCC Stage (7th)
| | | |
0.730
|
|
I
|
979 (67.5)
|
687 (63.7)
|
292 (63.2)
| |
|
II
|
167 (10.8)
|
111 (10.3)
|
56 (12.1)
| |
|
III
|
302 (19.6)
|
214 (19.8)
|
88 (19.0)
| |
|
IV
|
395 (6.0)
|
67 (6.2)
|
26 (5.6)
| |
|
Grade
| | | |
0.167
|
|
I/II
|
121 (7.9)
|
87 (8.1)
|
34 (7.4)
| |
|
III
|
588 (38.2)
|
429 (39.8)
|
159 (34.4)
| |
|
IV
|
398 (25.8)
|
266 (24.7)
|
132 (28.6)
| |
|
Unknown
|
434 (28.2)
|
297 (27.5)
|
137 (29.7)
| |
|
LN dissected, n
| | | |
0.154
|
|
No
|
318 (20.6)
|
217 (20.1)
|
101 (21.9)
| |
|
1–10
|
446 (28.9)
|
328 (30.4)
|
118 (25.5)
| |
|
> 10
|
777 (50.4)
|
534 (49.5)
|
243 (52.6)
| |
|
LN
| | | |
0.233
|
|
No dissection or Negative
|
1370 (88.9)
|
966 (89.5)
|
404 (87.4)
| |
|
Positive
|
171 (11.1)
|
113 (10.5)
|
58 (12.6)
| |
|
Organ Metastasis
| | | |
0.939
|
|
No
|
1505 (97.7)
|
1054 (97.7)
|
451 (97.6)
| |
|
Yes
|
36 (2.3)
|
25 (2.3)
|
11 (2.4)
| |
|
Radiotherapy
| | | |
0.312
|
|
No/Unknown
|
1509 (97.9)
|
1054 (97.7)
|
451 (98.5)
| |
|
Yes
|
32 (2.1)
|
25 (2.3)
|
7 (1.5)
| |
|
Chemotherapy
| | | |
0.800
|
|
No/Unknown
|
276 (17.9)
|
195 (18.1)
|
81 (17.5)
| |
|
Yes
|
1265 (82.1)
|
884 (81.9)
|
381 (82.5)
| |
- AJCC American Joint Committee on Cancer, LN lymph node
